GlassScriptPhysician profile
Bradley Don Barker
NPI 1619191731
$15,702.49
in general payments reported to CMS, 2019-2025
53 companies · $2,593 in 2025
The $2,593 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,697 · 2020: $2,101 · 2021: $1,896 · 2022: $2,166 · 2023: $2,075 · 2024: $2,175 · 2025: $2,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,842.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,754.29 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,607.40 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Novo Nordisk INC | $1,316.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,141.95 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $989.11 | 2019-2025 | |
| Lilly USA, LLC | $896.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $742.84 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Amgen INC. | $656.13 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Janssen Pharmaceuticals, INC | $639.59 | 2019-2025 | Spravato, Xarelto |
| Phathom Pharmaceuticals, INC. | $576.33 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $559.03 | 2019-2025 | Jardiance, Ofev |
| E.R. Squibb & Sons, L.L.C. | $470.37 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $424.53 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $422.45 | 2019-2023 | Ajovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.75 | 2019-2025 | Xifaxan, Trulance |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Barker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.